Cresco Labs Inc.
CRLBF · OTCMCIK 1832928fmd_0SR4NEA79S07PGM5R70QAY145AManufacturing · Medicinal Chemicals & Botanical ProductsTemplate: Standard
Coverage: Jan 01, 2019 to Dec 31, 2025, 7 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 129 | 476 | 822 | 843 | 771 | 724 | 656 |
| Cost of revenue | 83 | 270 | 415 | 436 | 409 | 360 | 331 |
| Gross profit | 46 | 207 | 406 | 407 | 362 | 364 | 325 |
| Realized investment gains (losses) | – | – | – | – | (0) | (0) | – |
| Provision for credit losses | – | – | – | – | 0 | 0 | 0 |
| Selling, general and administrative | 94 | 229 | 318 | 351 | 299 | 255 | 247 |
| Total operating expenses | – | – | – | – | 450 | 257 | 353 |
| Operating income | (34) | (23) | (217) | (84) | (88) | 107 | (28) |
| Interest expense | 8 | 31 | 51 | 58 | 44 | 38 | 42 |
| Interest and investment income | – | – | – | – | 2 | 3 | 4 |
| Other non-operating income (expense) | – | – | – | – | (59) | (118) | (67) |
| Income before taxes | (51) | (64) | (257) | (127) | (147) | (11) | (95) |
| Income tax expense | 14 | 29 | 40 | 89 | 33 | 50 | 45 |
| Net income from continuing operations | (65) | (93) | (297) | (216) | (180) | (60) | (140) |
| Net income | (43) | (102) | (320) | (212) | (176) | (74) | (135) |
| Net income to common shareholders | (43) | (82) | – | – | – | – | – |